Compare FWRD & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | RGNX |
|---|---|---|
| Founded | 1981 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.2M | 761.9M |
| IPO Year | 2024 | 2015 |
| Metric | FWRD | RGNX |
|---|---|---|
| Price | $21.76 | $8.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $38.50 | $29.13 |
| AVG Volume (30 Days) | 602.0K | ★ 865.1K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,269,573,000.00 | $10,393,000.00 |
| Revenue This Year | $6.77 | $116.76 |
| Revenue Next Year | $6.83 | $49.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $9.79 | $5.04 |
| 52 Week High | $32.47 | $16.19 |
| Indicator | FWRD | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 29.02 | 39.40 |
| Support Level | $16.46 | $7.80 |
| Resistance Level | $23.20 | $9.28 |
| Average True Range (ATR) | 1.44 | 0.63 |
| MACD | -0.50 | 0.22 |
| Stochastic Oscillator | 7.39 | 46.57 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.